1995 2003 2004 2005...Half of NNE Pharmaplan’s business was now outside Denmark. 2009 PRONOVA...
1
Highlights from our past 25 years 1991 NNE ESTABLISHED AS INDEPENDENT COMPANY. CEO was Per Andersen. 1995 NEW PROJECT OFFICE in Tianjin, outside of Beijing, to help Novozymes establish their first enzyme production facility in China. 1998 NOVOLET COMPLET, Hilleroed, Denmark. Handover of a highly automated Novo Nordisk plant for fill, finish and assembly of insulin pens based on a new manufactur- ing concept. 1997 NNE obtains the first ISO 9001 certification. 1999 HANS OLE VOIGT appointed new CEO. 2002 COMPLETION OF NOVOSEVEN PLANT – a new biotechnological plant for production of hemophilia medicine (FVII) for Novo Nor- disk in Hillerød. A fast-track engineering project completed in only 18 months. 2003 NEW BRANCH OFFICE in Chartres, France. NEW BRANCH OFFICE in Clayton, North Carolina, USA. NEW SWEDISH OFFICE south of Stockholm. HANDOVER OF IBP (insulin bulk plant) with 32.000 square meter. An investment of 2,5 billion DKK makes it NNE’s biggest project. 2004 HAND-OVER NOVO NORDISK PIA2 PLANT. The 7,000 m² green field facility was completed in only 14,5 months, using pre-assembled units and a completely modu- larized automation system that was built and tested off-site to ensure fast-track construction. 2005 VACCINE FACILITY for Bavarian Nordic in Kvistgaard, Denmark, built in 11 months. NNE WINS FACILITY- OF-THE-YEAR AWARD for Novo Nordisk’s NovoSeven ® manufacturing facility in Hillerød. 2005/2006 PIA3 AND PIA4. Built with same technique as PIA2, PIA3 and PIA4 are handed over. The total investments of these three facilities exceeds to DKK 2 billion. 2007 COMPLETION OF GSK ST. ARMAND. The first major fixed- priced project outside Denmark. NNE´s part of this project had a Total Investment Cost responding to EUR 200 million. Delivered in joint cooperation between Den- mark and France. Business outside Novo Nordisk grew bigger than the Novo Nordisk business. 2008 INTERNATIONAL FOOTPRINT Half of NNE Pharmaplan’s business was now outside Denmark. 2009 PRONOVA BIOPHARM – the biggest contract to date, DKK 400 million was completed in18 months after basic design. ROCHE NPK PROJECT completed. OUR MODEL AND OUR WIKI implemented. 2011 NEW CEO, MORTEN NIELSEN and new organisation based on regional expansion. SIX ESSENTIALS LAUNCH. 2012 COMPLETION OF THE ‘BLAIR’ PROJECT – one of the world’s most advanced enzyme plants for biofuel for Novozymes. This is one of the largest cross- regional collaborations in NNE Pharmaplan’s history. HANDOVER of groundbreak- ing cGMP Biotechnological Pilot Plant to UCB in Belgium. 2013 COMPLETION OF UCB’S first large-scale biotech com- mercial production facility in Switzerland. 2015 HANDOVER of new manufac- turing facility for OSD products for AstraZeneca. AstraZeneca wins Facility of the Year award for this facility. JESPER KLØVE appointed new CEO. 2001 BUILD A PLANT IN 12 MONTHS vision set. SITE KALUNDBORG and SITE HILLERØD are estab- lished as part of NNE’s new growth strategy. + = NNE PHARMAPLAN WAS ESTABLISHED. NNE merged with the German engineering company Pharmaplan GmbH.
Transcript of 1995 2003 2004 2005...Half of NNE Pharmaplan’s business was now outside Denmark. 2009 PRONOVA...
-
Highlights from our past 25 years
1991 NNE ESTABLISHED AS INDEPENDENT COMPANY. CEO was Per Andersen.
1995 NEW PROJECT OFFICE in Tianjin, outside of Beijing, to help Novozymes establish their first enzyme production facility in China.
1998NOVOLET COMPLET, Hilleroed, Denmark. Handover of a highly automated Novo Nordisk plant for fill, finish and assembly of insulin pens based on a new manufactur-ing concept.
1997NNE obtains the first ISO 9001 certification.
1999HANS OLE VOIGT appointed new CEO.
2002COMPLETION OF NOVOSEVEN PLANT – a new biotechnological plant for production of hemophilia medicine (FVII) for Novo Nor-disk in Hillerød. A fast-track engineering project completed in only 18 months.
2003NEW BRANCH OFFICE in Chartres, France.
NEW BRANCH OFFICE in Clayton, North Carolina, USA.
NEW SWEDISH OFFICE south of Stockholm.
HANDOVER OF IBP (insulin bulk plant) with 32.000 square meter. An investment of 2,5 billion DKK makes it NNE’s biggest project.
2004HAND-OVER NOVO NORDISK PIA2 PLANT. The 7,000 m² green field facility was completed in only 14,5 months, using pre-assembled units and a completely modu-larized automation system that was built and tested off-site to ensure fast-track construction.
2005VACCINE FACILITY for Bavarian Nordic in Kvistgaard, Denmark, built in 11 months.
NNE WINS FACILITY- OF-THE-YEAR AWARD for Novo Nordisk’s NovoSeven® manufacturing facility in Hillerød.
2005/2006PIA3 AND PIA4. Built with same technique as PIA2, PIA3 and PIA4 are handed over. The total investments of these three facilities exceeds to DKK 2 billion.
2007COMPLETION OF GSK ST. ARMAND. The first major fixed- priced project outside Denmark. NNE´s part of this project had a Total Investment Cost responding to EUR 200 million. Delivered in joint cooperation between Den-mark and France.
Business outside Novo Nordisk grew bigger than the Novo Nordisk business.
2008INTERNATIONAL FOOTPRINT Half of NNE Pharmaplan’s business was now outside Denmark. 2009
PRONOVA BIOPHARM – the biggest contract todate, DKK 400 million wascompleted in18 monthsafter basic design.
ROCHE NPK PROJECT completed.
OUR MODEL AND OUR WIKI implemented.
2011NEW CEO, MORTEN NIELSEN and new organisation based on regional expansion.
SIX ESSENTIALS LAUNCH.
2012COMPLETION OF THE ‘BLAIR’ PROJECT – one of the world’s mostadvanced enzyme plants forbiofuel for Novozymes. Thisis one of the largest cross- regional collaborations inNNE Pharmaplan’s history.
HANDOVER of groundbreak-ing cGMP Biotechnological Pilot Plant to UCB in Belgium.
2013COMPLETION OF UCB’S first large-scale biotech com-mercial production facility in Switzerland.
2015HANDOVER of new manufac-turing facility for OSD products for AstraZeneca. AstraZeneca wins Facility of the Year award for this facility.
JESPER KLØVE appointed new CEO.
2001BUILD A PLANT IN 12 MONTHS vision set.
SITE KALUNDBORG and SITE HILLERØD are estab-lished as part of NNE’s new growth strategy.
+ =
NNE PHARMAPLAN WAS ESTABLISHED. NNE merged with the German engineering company Pharmaplan GmbH.
